CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-07905-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Yizhen Pang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Magnetic Resonance Imaging, Receptors, CXCR4, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the foundation of Natural Science Foundation of Shandong, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
BACKGROUND: This study aimed to evaluate the diagnostic performance of [¹⁸F]AlF-NOTA-QHY-04 PET/CT, a novel CXCR4-targeted imaging agent, in detecting primary central nervous system lymphoma (PCNSL) at initial diagnosis and suspected recurrence, in comparison with contrast-enhanced magnetic resonance imaging (CE-MRI) and [¹⁸F]FDG PET/CT. METHODS: We prospectively enrolled patients with suspected PCNSL between September 2022 and December 2024. A total of 29 patients underwent both CE-MRI and [¹⁸F]AlF-NOTA-QHY-04 PET/CT, with 20 patients also receiving [¹⁸F]FDG PET/CT. Biopsy pathology served as the reference standard for newly diagnosed lesions. Recurrence was assessed using a composite reference standard based on CE-MRI, clinical follow-up, and cerebrospinal fluid (CSF) findings when available; an exploratory sensitivity analysis excluded MRI-dependent cases. Imaging parameters including the maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and tumor-to-background ratios (TBR) were calculated. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis and compared. RESULTS: Six treatment-naïve patients (14 lesions) and 16 patients with recurrence (16 lesions) were confirmed, along with 7 patients without recurrence. Both primary and recurrent lesions showed intense tracer uptake on [¹⁸F]AlF-NOTA-QHY-04 PET/CT, characterized by notably high TBR. In the 20-patient subgroup undergoing both PET scans, [¹⁸F]AlF-NOTA-QHY-04 demonstrated significantly lower absolute SUVmax compared to [¹⁸F]FDG (median: 2.42 vs. 11.73, P 0.05) and significantly superior to [¹⁸F]FDG PET/CT (43.75% and 59.09%, P = 0.023). ROC analysis identified [¹⁸F]AlF-NOTA-QHY-04 SUVmax as the optimal diagnostic parameter (AUC = 0.979). CONCLUSION: [¹⁸F]AlF-NOTA-QHY-04 PET/CT demonstrated high tumor-to-background contrast in PCNSL, consistent with its low background brain uptake. It shows diagnostic accuracy comparable to CE-MRI and significantly superior to [¹⁸F]FDG PET/CT, demonstrating high potential as a valuable imaging tool for the diagnosis and restaging of PCNSL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
- Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
- Department of Lymphoma and Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, China.
- Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. sdyujinming@163.com.
- Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China. sdyujinming@163.com.
- Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China. leoc…
ORCID-Profile: Haojun Chen
Förderung
- National Natural Science Foundation of China
- the foundation of Natural Science Foundation of Shandong
- Taishan Scholar Foundation of Shandong Province
- Distinguished Middle-Aged and Young Scientist Encourage and Reward Foundation of Shandong Province
- China Postdoctoral Science Foundation
- Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
- Shandong Excellent Youth Science Fund Project (Overseas)
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Pang, Y., Xing, L., Liu, J., Zhao, X., Li, C., Xu, S., Pei, J., Yu, J., Chen, H., & Liu, J. (2026). CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07905-3
Vancouver
Pang Y, Xing L, Liu J, Zhao X, Li C, Xu S, et al. CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07905-3
BibTeX
@article{Pang2026,
author = {Pang, Yizhen and Xing, Lijie and Liu, Jingru and Zhao, Xinzhi and Li, Chenzhen and Xu, Shengnan and Pei, Jinli and Yu, Jinming and Chen, Haojun and Liu, Jie},
title = {CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-07905-3}
}
EUVIMED